Get started
Author

Selina Chen‐Kiang

Observed names: Chen-Kiang Selina, Chen-Kiang, Selina, S Chen-Kiang, S Chen‐Kiang, S. Chen-Kiang, S. Chen‐Kiang, Selina Chen- Kiang, Selina Chen-Kiang, Selina Chen-kiang, Selina Y. Chen-Kiang
Observed institutions: Memorial Sloan Kettering Cancer Center, Montefiore Medical Center, NewYork–Presbyterian Hospital, The University of Texas at San Antonio Health Science Center, Pfizer (United States), Ludwig Cancer Research, Princeton University, Cornell University, Oklahoma Medical Research Foundation, NYU Langone Health, Geron (United States), Ludwig Cancer Research, Weill Cornell Medicine, Weill Cornell Medical Center, New York University, Columbia University, University of Birmingham, Rockefeller University, University of Oklahoma, Icahn School of Medicine at Mount Sinai
ORCID: 0000-0002-8549-6177
Observed ORCID: 0000-0002-8549-6177
OpenAlex ID: A5000554189
International Myeloma Working Group molecular classification of multiple myeloma: spotlight review
2009 · R Fonseca, P L Bergsagel, et al. · Leukemia · 886
Requirement of Serine Phosphorylation for Formation of STAT-Promoter Complexes
1995 · Xiaokui Zhang, John Blenis, et al. · Science · 573
AID Is Required for c-myc/IgH Chromosome Translocations In Vivo
2004 · Almudena R. Ramiro, Mila Jankovic, et al. · Cell · 465
PDF
Attenuation of Apoptosis Underlies B Lymphocyte Stimulator Enhancement of Humoral Immune Response
2000 · Richard K.G. Do, Eunice Hatada, et al. · The Journal of Experimental Medicine · 431
Outcome of Deferred Initial Therapy in Mantle-Cell Lymphoma
2009 · Peter Martin, Amy Chadburn, et al. · Journal of Clinical Oncology · 339
Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma
2012 · John P. Leonard, Ann S. LaCasce, et al. · Blood · 299
PDF
Postibrutinib outcomes in patients with mantle cell lymphoma
2016 · Peter Martin, Kami Maddocks, et al. · Blood · 294
PDF
RETRACTED: Coordinated Silencing of MYC-Mediated miR-29 by HDAC3 and EZH2 as a Therapeutic Target of Histone Modification in Aggressive B-Cell Lymphomas
2012 · Xinwei Zhang, Xiaohong Zhao, et al. · Cancer Cell · 276
PDF
Cell-Cycle Reprogramming for PI3K Inhibition Overrides a Relapse-Specific C481S BTK Mutation Revealed by Longitudinal Functional Genomics in Mantle Cell Lymphoma
2014 · David Chiron, Maurizio Di Liberto, et al. · Cancer Discovery · 272
A Novel Orally Active Small Molecule Potently Induces G1 Arrest in Primary Myeloma Cells and Prevents Tumor Growth by Specific Inhibition of Cyclin-Dependent Kinase 4/6
2006 · Linda B. Baughn, Maurizio Di Liberto, et al. · Cancer Research · 224
PDF
Retinoblastoma protein directly interacts with and activates the transcription factor NF-IL6.
1996 · P L Chen, D J Riley, et al. · Proceedings of the National Academy of Sciences · 209
Fos and Jun repress transcription activation by NF-IL6 through association at the basic zipper region
1994 · W Hsu, T K Kerppola, et al. · Molecular and Cellular Biology · 200
BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma.
2007 · Ruben Niesvizky, David S. Jayabalan, et al. · Blood · 184
Therapeutic Targeting of the Cyclin D3:CDK4/6 Complex in T Cell Leukemia
2012 · Catherine M. Sawai, Jacquelyn Freund, et al. · Cancer Cell · 183
PDF
The cancer-testis antigens CT7 (MAGE-C1) and MAGE-A3/6 are commonly expressed in multiple myeloma and correlate with plasma-cell proliferation
2005 · Achim A. Jungbluth, Scott Ely, et al. · Blood · 182
Immunomodulation by anticancer cell cycle inhibitors
2020 · Giulia Petroni, Silvia C. Formenti, et al. · Nature reviews. Immunology · 162
Induction of Cell Cycle Arrest and B Cell Terminal Differentiation by CDK Inhibitor p18 and IL-6
1997 · Leslie Morse, Dongquan Chen, et al. · Immunity · 159
PDF
The addition of 5′ cap structures occurs early in hnRNA synthesis and prematurely terminated molecules are capped
1980 · M. Salditt-Georgieff, M. Harpold, et al. · Cell · 159
Selective inhibition of protein arginine methyltransferase 5 blocks initiation and maintenance of B-cell transformation
2015 · Lapo Alinari, Kiran V. Mahasenan, et al. · Blood · 148
PDF
NF-κB1 p50 Is Required for BLyS Attenuation of Apoptosis but Dispensable for Processing of NF-κB2 p100 to p52 in Quiescent Mature B Cells
2003 · Eunice N Hatada, Richard K G Do, et al. · The Journal of Immunology · 134
Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma
2010 · Ruben Niesvizky, Scott Ely, et al. · Cancer · 133
PDF
N-6-methyl-adenosine in adenovirus type 2 nuclear RNA is conserved in the formation of messenger RNA
1979 · Selina Chen-Kiang, Joseph R. Nevins, et al. · Journal of Molecular Biology · 131
Disruption of the MYC-miRNA-EZH2 loop to suppress aggressive B-cell lymphoma survival and clonogenicity
2013 · X Zhao, T Lwin, et al. · Leukemia · 116
Mutually Exclusive Cyclin-Dependent Kinase 4/Cyclin D1 and Cyclin-Dependent Kinase 6/Cyclin D2 Pairing Inactivates Retinoblastoma Protein and Promotes Cell Cycle Dysregulation in Multiple Myeloma
2005 · Scott Ely, Maurizio Di Liberto, et al. · Cancer Research · 115
CDK Inhibitor p18INK4c Is Required for the Generation of Functional Plasma Cells
2002 · Michelle R. Tourigny, Josie Ursini-Siegel, et al. · Immunity · 109
PDF
Works count: 293
Citation count: 10,010
H-index: 55
I10-index: 103
Year
Topic
Type